Switch from intravenous to enteral moxifloxacin in critically ill patients: A pilot study

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 11, 2012, Pages 874-878

  De Smet, Julie ^a   Colpaert, Kirsten ^b   De Paepe, Peter ^c   Van Bocxlaer, Jan ^a   Decruyenaere, Johan ^b   Boussery, Koen ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Enteral; Intensive care; Intravenous; Moxifloxacin; Pharmacokinetics

Indexed keywords

MOXIFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG EFFICACY; HUMAN; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CREATINE; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PILOT PROJECTS; PNEUMONIA; PROSPECTIVE STUDIES; QUINOLINES; THERAPEUTIC EQUIVALENCY;

EID: 84867827641     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.693194     Document Type: Article

References (21)

1. Balfour JA, Lamb HM. Moxifloxacin - a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000;59:115 - 39.
2. Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005;41:S136 - 43.
3. Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother 2009;64:188 - 99.
4. Ballow C, Lettieri J, Agarwal V, Liu P, Stass H, Sullivan JT. Absolute bioavailability of moxifloxacin. Clin Ther 1999;21: 513 - 22.
5. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43:83 - 90.
6. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22:255 - 71.
7. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998;34:25 - 56.
8. Haglund U. Systemic mediators released from the gut in critical illness. Crit Care Med 1993;21:S15 - 8.
9. De Smet J, Boussery K, Colpaert K, De Sutter P, De Paepe P, Decruyenaere J, Van Bocxlaer J. Pharmacokinetics of fluoroquinolones in critical care patients: a bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. J Chromatogr B 2009;877:961 - 7.
10. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010;99:306 - 14.
11. Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999;43:1508 - 10.
12. S chentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates - part 2: human trials. Ann Pharmacother 2003;37:1478 - 88.
13. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin - a new paradigm for early clinical trials. JAMA 1998;279:125 - 9.
14. Craig WA. Does the dose matter? Clin Infect Dis 2001;33: S233 - 7.
15. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999;58:29 - 36.
16. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones - focus on respiratory tract infections. Drugs 2002;62:13 - 59.
17. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50:99 - 110.
18. Dumoulin A, Janssen A, De Waele JJ, Decruyenaere J, Hoste EA. Epidemiology of hyperfiltration in ICU patients. Intensive Care Med 2010;36:S140.
19. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1 - 16.
20. Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001;40:1 - 9.
21. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010;36:332 - 9.